Early CAR T-patient identification in 2L DLBCL – The UK experience
A webinar with Dr Robin Sanderson, hematologist at King´s College Hospital in London, UK, sharing his experiences in treating patients with DLBCL in 2L, including his thoughts on patient identification, the importance of early referral, as well as what is important when it comes to the collaboration between referring clinics and treating clinics.
Prof. Mats Jerkeman moderated the webinar and held an introduction about DLBCL and CAR T treatment in Sweden.
(Webinar approx. 45 minutes)
Also take part in an interview where Dr. Sanderson discusses various aspects linked to the webinar.
(The film clips are approx. 2.5 minutes long)
Cost-effectiveness analysis of YESCARTA® (axicabtagene ciloleucel) in 2L DLBCL in Sweden
During EHA 2024, Viktor Hedlöf Kanje, Market Access Lead at Gilead, presented
a Swedish cost-effectiveness analysis of YESCARTA® (axicabtagene ciloleucel) in 2L DLBCL. Listen to the results of the analysis in the interview with Viktor.
(video about 2 min).
CAR T patient selection and Real World Evidence
In this webinar Gunilla Enbland and Mats Jerkeman, two leading CAR T experts, share their practical insights and considerations on patient selection, real world evidence and they also review a patient case.
SE-TEC-0040 | 09/2024
